Redeye comments on Nanologica following yesterday’s after-market announcement of the acquisition of ...
Suominen’s challenges continue at least in the short-term, but the company is now taking more signif...
Analysguiden räknar med en omsättning om 2,1 mdkr och ett justerad rörelseresultat om 299 mkr för Be...
Redeye provides its initial take on Lifco’s Q4 2025 report, which missed our projections by 3% on sa...
Besqab’s Q4 looks strong, with solid earnings growth and a high number of starts.
Redeye comments on Enea’s Q4 2025 report were sales fell short of expectations, yet profitability ex...
Suominen's Q4 was weak with soft markets and a continued negative impact from US incidents burdening...
Smart Eye has reached a key milestone by being selected by a Japanese OEM to supply DMS software inc...
Inderes’ Oct-Nov sales show that we underestimated the bounce-back of the timing issue, which caused...
Scanfil's guidance for 2026 indicates net sales growth of 16-31% we calculate.
We regard the refresh cycle to have begun in Q2/25.
Redeye comments on Magle’s strategic pivot toward profitability, operational discipline, and sustain...
* Q4e sales SEK 45m (58m), adj. EBIT SEK 10m (19m) * We cut '26e-'27e sales and EBIT by 10% and 22-1...
Suominen Q4 comparable EBITDA of EUR 1.9m came 60% below Vara Research consensus expectations.
Suominen’s Q4 results were lower than estimated as excess nonwovens capacity still hurt volumes, lea...
Redeye comments on q.beyond’s preliminary Q4 figures, showing stronger EBITDA than expected.
Redeye comments on Gentoo Media’s preliminary Q4-results where EBITDA was above our forecast, while ...
Physitrack released preliminary Q4 2025 figures this morning, which were broadly in line with our ex...
Our estimate revisions are driven by USD/SEK movements (down almost 7% since our Q3 review) lowering...
* 27% y-o-y organic sales growth in Q4'25e * No change to financial targets expected Q4'25 results d...
